DiaMedica to Participate in Three Investment Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy DMAC?
Source: Newsfilter
- Investment Conference Schedule: DiaMedica Therapeutics will participate in the TD Cowen 46th Annual Healthcare Conference on March 2, 2026, in Boston, where CEO Rick Pauls and Chief Medical Officer Julie Krop will engage in a fireside chat, showcasing the company's latest advancements in treating serious ischemic diseases.
- Global Healthcare Conference: The company will also attend the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, where CEO Rick Pauls will conduct a fireside chat, further enhancing the company's visibility among investors.
- Presentation Opportunity: On March 11, 2026, at the Leerink Partners Global Healthcare Conference, Rick Pauls will present the company, aiming to attract potential investors and highlight DiaMedica's R&D achievements and future plans.
- Management Interaction: DiaMedica encourages arrangements for 1-on-1 meetings with management to facilitate deeper engagement with investors, further strengthening the relationship between the company and its investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DMAC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DMAC
Wall Street analysts forecast DMAC stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.790
Low
12.00
Averages
17.00
High
25.00
Current: 7.790
Low
12.00
Averages
17.00
High
25.00
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DiaMedica Receives No Objection Letter from Health Canada to Initiate Phase 2 Study for Early-Onset Preeclampsia
- Regulatory Milestone: DiaMedica Therapeutics Inc. has received a No Objection Letter from Health Canada, allowing it to initiate the Phase 2 clinical trial of DM199 in early-onset preeclampsia in 2026, marking a significant advancement in addressing unmet medical needs in this area.
- Clinical Trial Design: The trial will evaluate the safety and tolerability of DM199 in pregnant women between 24 and 32 weeks of gestation, administered subcutaneously every three days at three different dose levels, aiming to provide new treatment options for early-onset preeclampsia patients.
- Market Demand: Recent NPR coverage highlights the urgent need for new treatments for preeclampsia, with DM199 being viewed as a promising therapeutic approach that could significantly improve maternal health outcomes if successfully developed, addressing a significant unmet medical need.
- International Expansion Plans: Following regulatory approvals, DiaMedica plans to expand the trial into the United States and the United Kingdom, enhancing its competitive position in the global market and laying the groundwork for future commercialization.
See More
Acute Ischemic Stroke Market Set for Growth Driven by Innovative Therapies
- Growth Drivers: The acute ischemic stroke market is expected to experience significant growth from 2026 to 2036, primarily driven by increased awareness of symptoms, advancements in acute stroke care, and a robust pipeline of new therapies, particularly lenzocimab, DM199, and milvexian.
- Market Size Forecast: By 2036, the acute ischemic stroke treatment market is projected to continue expanding, with the United States holding the largest market share; in 2025, approximately 1.8 million new cases of acute ischemic stroke are expected in the 7MM, indicating strong market demand.
- Clinical Progress of New Therapies: Several innovative acute ischemic stroke drugs are currently in clinical trials, including Acticor Biotech's Glenzocimab and DiaMedica Therapeutics' DM199, which are anticipated to transform the market landscape by providing more effective treatment options in the coming years.
- Challenges and Opportunities: While the acute ischemic stroke market faces challenges from high mortality and morbidity rates, the launch of new drugs and advancements in stem cell therapies present significant opportunities for pharmaceutical companies, likely driving long-term growth in the industry.
See More
DiaMedica to Participate in Three Investment Conferences
- Investment Conference Schedule: DiaMedica Therapeutics will participate in the TD Cowen 46th Annual Healthcare Conference on March 2, 2026, in Boston, where CEO Rick Pauls and Chief Medical Officer Julie Krop will engage in a fireside chat, showcasing the company's latest advancements in treating serious ischemic diseases.
- Global Healthcare Conference: The company will also attend the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, where CEO Rick Pauls will conduct a fireside chat, further enhancing the company's visibility among investors.
- Presentation Opportunity: On March 11, 2026, at the Leerink Partners Global Healthcare Conference, Rick Pauls will present the company, aiming to attract potential investors and highlight DiaMedica's R&D achievements and future plans.
- Management Interaction: DiaMedica encourages arrangements for 1-on-1 meetings with management to facilitate deeper engagement with investors, further strengthening the relationship between the company and its investors.
See More
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
- Incentive Options: On January 15, 2026, DiaMedica granted 50,000 stock options to a newly hired non-executive employee as a material inducement for their acceptance of employment, aligning with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to attracting talent.
- Exercise Price: The options have an exercise price of $8.54 per share, matching the closing price of the company's common stock on the grant date, ensuring that employees have a strong financial incentive to remain with the company long-term.
- Vesting Schedule: The options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 12 quarterly installments thereafter, designed to encourage continued service and enhance employee loyalty.
- Strategic Focus: DiaMedica is dedicated to developing innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, and this stock option grant not only attracts talent but also supports its long-term growth in the biopharmaceutical sector.
See More
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
- Options Grant: On January 15, 2026, DiaMedica Therapeutics granted 50,000 stock options to a newly hired non-executive employee as a material inducement for their acceptance of employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The options have an exercise price of $8.54 per share, matching the closing price of the company's common stock on January 15, 2026, indicating the company's commitment to employee incentives.
- Vesting Schedule: The options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 12 quarterly installments, ensuring long-term incentives for employees who continue their service with the company.
- Strategic Implications: This options grant not only enhances the company's ability to attract and retain talent but also reflects DiaMedica's ongoing commitment to growth in the clinical-stage biopharmaceutical sector and investment in its workforce.
See More
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
See More
DiaMedica Receives No Objection Letter from Health Canada to Initiate Phase 2 Study for Early-Onset Preeclampsia
- Regulatory Milestone: DiaMedica Therapeutics Inc. has received a No Objection Letter from Health Canada, allowing it to initiate the Phase 2 clinical trial of DM199 in early-onset preeclampsia in 2026, marking a significant advancement in addressing unmet medical needs in this area.
- Clinical Trial Design: The trial will evaluate the safety and tolerability of DM199 in pregnant women between 24 and 32 weeks of gestation, administered subcutaneously every three days at three different dose levels, aiming to provide new treatment options for early-onset preeclampsia patients.
- Market Demand: Recent NPR coverage highlights the urgent need for new treatments for preeclampsia, with DM199 being viewed as a promising therapeutic approach that could significantly improve maternal health outcomes if successfully developed, addressing a significant unmet medical need.
- International Expansion Plans: Following regulatory approvals, DiaMedica plans to expand the trial into the United States and the United Kingdom, enhancing its competitive position in the global market and laying the groundwork for future commercialization.
See More
Acute Ischemic Stroke Market Set for Growth Driven by Innovative Therapies
- Growth Drivers: The acute ischemic stroke market is expected to experience significant growth from 2026 to 2036, primarily driven by increased awareness of symptoms, advancements in acute stroke care, and a robust pipeline of new therapies, particularly lenzocimab, DM199, and milvexian.
- Market Size Forecast: By 2036, the acute ischemic stroke treatment market is projected to continue expanding, with the United States holding the largest market share; in 2025, approximately 1.8 million new cases of acute ischemic stroke are expected in the 7MM, indicating strong market demand.
- Clinical Progress of New Therapies: Several innovative acute ischemic stroke drugs are currently in clinical trials, including Acticor Biotech's Glenzocimab and DiaMedica Therapeutics' DM199, which are anticipated to transform the market landscape by providing more effective treatment options in the coming years.
- Challenges and Opportunities: While the acute ischemic stroke market faces challenges from high mortality and morbidity rates, the launch of new drugs and advancements in stem cell therapies present significant opportunities for pharmaceutical companies, likely driving long-term growth in the industry.
See More
DiaMedica to Participate in Three Investment Conferences
- Investment Conference Schedule: DiaMedica Therapeutics will participate in the TD Cowen 46th Annual Healthcare Conference on March 2, 2026, in Boston, where CEO Rick Pauls and Chief Medical Officer Julie Krop will engage in a fireside chat, showcasing the company's latest advancements in treating serious ischemic diseases.
- Global Healthcare Conference: The company will also attend the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, where CEO Rick Pauls will conduct a fireside chat, further enhancing the company's visibility among investors.
- Presentation Opportunity: On March 11, 2026, at the Leerink Partners Global Healthcare Conference, Rick Pauls will present the company, aiming to attract potential investors and highlight DiaMedica's R&D achievements and future plans.
- Management Interaction: DiaMedica encourages arrangements for 1-on-1 meetings with management to facilitate deeper engagement with investors, further strengthening the relationship between the company and its investors.
See More
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
- Incentive Options: On January 15, 2026, DiaMedica granted 50,000 stock options to a newly hired non-executive employee as a material inducement for their acceptance of employment, aligning with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to attracting talent.
- Exercise Price: The options have an exercise price of $8.54 per share, matching the closing price of the company's common stock on the grant date, ensuring that employees have a strong financial incentive to remain with the company long-term.
- Vesting Schedule: The options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 12 quarterly installments thereafter, designed to encourage continued service and enhance employee loyalty.
- Strategic Focus: DiaMedica is dedicated to developing innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, and this stock option grant not only attracts talent but also supports its long-term growth in the biopharmaceutical sector.
See More
DiaMedica Therapeutics Grants 50,000 Stock Options to New Employee
- Options Grant: On January 15, 2026, DiaMedica Therapeutics granted 50,000 stock options to a newly hired non-executive employee as a material inducement for their acceptance of employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price: The options have an exercise price of $8.54 per share, matching the closing price of the company's common stock on January 15, 2026, indicating the company's commitment to employee incentives.
- Vesting Schedule: The options will vest 25% on the one-year anniversary of the grant date, with the remaining 75% vesting in 12 quarterly installments, ensuring long-term incentives for employees who continue their service with the company.
- Strategic Implications: This options grant not only enhances the company's ability to attract and retain talent but also reflects DiaMedica's ongoing commitment to growth in the clinical-stage biopharmaceutical sector and investment in its workforce.
See More
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
See More
